Literature DB >> 18690496

Interferon-beta responders and non-responders. A biological approach.

Antonio Bertolotto1, Francesca Gilli.   

Abstract

The therapeutic benefits of interferon-beta are limited, as some patients with multiple sclerosis (MS) do not respond to therapy. Based on their biological characteristics, non-responsive patients can be divided into three subgroups: genetic, pharmacological and pathogenetic non-responders. In order to tailor the best treatment in both newly diagnosed MS patients and those already receiving treatment, the neurologist must carefully consider the risk of treating non-responders.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18690496     DOI： 10.1007/s10072-008-0941-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  6 in total

1.  Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Authors:  Jordi Río; Carlos Nos; Mar Tintoré; Nieves Téllez; Ingrid Galán; Raúl Pelayo; Manuel Comabella; Xavier Montalban
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

Review 2.  A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.

Authors:  D Karussis; L D Biermann; S Bohlega; A Boiko; M Chofflon; F Fazekas; M Freedman; S Gebeily; R Gouider; E Havrdova; G Jakab; R Karabudak; A Miller
Journal:  Eur J Neurol       Date:  2006-01       Impact factor: 6.089

3.  IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells.

Authors:  Philippe Mathurin; Shigang Xiong; Kusum K Kharbanda; Nary Veal; Takeo Miyahara; Kenta Motomura; Richard A Rippe; Max G Bachem; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-06       Impact factor: 4.052

4.  Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

Authors:  F Gilli; F Marnetto; M Caldano; A Sala; S Malucchi; A Di Sapio; M Capobianco; A Bertolotto
Journal:  J Neuroimmunol       Date:  2005-01       Impact factor: 3.478

5.  Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Authors:  Francesca Gilli; Antonio Bertolotto; Arianna Sala; Francine Hoffmann; Marco Capobianco; Simona Malucchi; Tracy Glass; Ludwig Kappos; Raija L P Lindberg; David Leppert
Journal:  Brain       Date:  2003-11-07       Impact factor: 13.501

6.  Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

Authors:  A-M Vallittu; M Halminen; J Peltoniemi; J Ilonen; I Julkunen; A Salmi; J-P Erälinna
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910
  6 in total
  8 in total

Review 1.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.

Authors:  DeRen Huang
Journal:  Neurosci Bull       Date:  2015-12       Impact factor: 5.203

3.  Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Authors:  Marsilio Adriani; Petra Nytrova; Cyprien Mbogning; Signe Hässler; Karel Medek; Poul Erik H Jensen; Paul Creeke; Clemens Warnke; Kathleen Ingenhoven; Bernhard Hemmer; Claudia Sievers; Raija Lp Lindberg Gasser; Nicolas Fissolo; Florian Deisenhammer; Zsolt Bocskei; Vincent Mikol; Anna Fogdell-Hahn; Eva Kubala Havrdova; Philippe Broët; Pierre Dönnes; Claudia Mauri; Elizabeth C Jury
Journal:  JCI Insight       Date:  2018-06-07

4.  Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Authors:  Antonio Bertolotto; Marco Capobianco; Maria Pia Amato; Elisabetta Capello; Ruggero Capra; Diego Centonze; Maria Di Ioia; Antonio Gallo; Luigi Grimaldi; Luisa Imberti; Alessandra Lugaresi; Chiara Mancinelli; Maria Giovanna Marrosu; Lucia Moiola; Enrico Montanari; Silvia Romano; Luigina Musu; Damiano Paolicelli; Francesco Patti; Carlo Pozzilli; Silvia Rossi; Marco Salvetti; Gioachino Tedeschi; Maria Rosaria Tola; Maria Trojano; Maria Troiano; Mauro Zaffaroni; Simona Malucchi
Journal:  Neurol Sci       Date:  2013-12-29       Impact factor: 3.307

5.  Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Authors:  Richard A Rudick; M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jie Na; Jennifer Shrock; Anupama Josyula; Elizabeth Fisher; Richard M Ransohoff
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

6.  Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.

Authors:  Valentina Durastanti; Alessandra Lugaresi; Placido Bramanti; Mariapia Amato; Paolo Bellantonio; Giovanna De Luca; Orietta Picconi; Roberta Fantozzi; Laura Locatelli; Annalisa Solda'; Edoardo Sessa; Rocco Totaro; Silvia Marino; Valentina Zipoli; Marino Zorzon; Enrico Millefiorini
Journal:  J Transl Med       Date:  2011-04-18       Impact factor: 5.531

7.  Association of CD58 Polymorphism with Multiple Sclerosis and Response to Interferon ß Therapy in A Subset of Iranian Population.

Authors:  Sara Torbati; Fatemeh Karami; Majid Ghaffarpour; Mahdi Zamani
Journal:  Cell J       Date:  2015-01-13       Impact factor: 2.479

8.  Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.

Authors:  Mahtab Fattahi; Nahid Eskandari; Fattah Sotoodehnejadnematalahi; Vahid Shaygannejad; Mohammad Kazemi
Journal:  Cell J       Date:  2019-09-08       Impact factor: 2.479
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.